Literature DB >> 22673573

Cyclic AMP-specific phosphodiesterase, PDE8A1, is activated by protein kinase A-mediated phosphorylation.

Kim M Brown1, Louisa C Y Lee, Jane E Findlay, Jonathan P Day, George S Baillie.   

Abstract

The cyclic AMP-specific phosphodiesterase PDE8 has been shown to play a pivotal role in important processes such as steroidogenesis, T cell adhesion, regulation of heart beat and chemotaxis. However, no information exists on how the activity of this enzyme is regulated. We show that under elevated cAMP conditions, PKA acts to phosphorylate PDE8A on serine 359 and this action serves to enhance the activity of the enzyme. This is the first indication that PDE8 activity can be modulated by a kinase, and we propose that this mechanism forms a feedback loop that results in the restoration of basal cAMP levels.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22673573     DOI: 10.1016/j.febslet.2012.04.033

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene.

Authors:  Vladimir T Manchev; Morgane Hilpert; Eliane Berrou; Ziane Elaib; Achille Aouba; Siham Boukour; Sylvie Souquere; Gerard Pierron; Philippe Rameau; Robert Andrews; François Lanza; Regis Bobe; William Vainchenker; Jean-Philippe Rosa; Marijke Bryckaert; Najet Debili; Remi Favier; Hana Raslova
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

Review 2.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

3.  Non-raft adenylyl cyclase 2 defines a cAMP signaling compartment that selectively regulates IL-6 expression in airway smooth muscle cells: differential regulation of gene expression by AC isoforms.

Authors:  Amy S Bogard; Anna V Birg; Rennolds S Ostrom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-22       Impact factor: 3.000

Review 4.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

5.  Phosphodiesterase activity is regulated by CC2D1A that is implicated in non-syndromic intellectual disability.

Authors:  Azza Al-Tawashi; Chris Gehring
Journal:  Cell Commun Signal       Date:  2013-07-04       Impact factor: 5.712

6.  Effect of Roflumilast in airways disorders via dual inhibition of phosphodiesterase and Ca2+-channel.

Authors:  Faisal Imam; Najeeb Ur Rehman; Mohd Nazam Ansari; Wajhul Qamar; Muhammad Afzal; Khalid Saad Alharbi
Journal:  Saudi Pharm J       Date:  2020-04-25       Impact factor: 4.330

Review 7.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Authors:  Selena Vigano; Dimitrios Alatzoglou; Melita Irving; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; George Coukos
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

8.  The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.

Authors:  Ashleigh M Byrne; Christina Elliott; Ralf Hoffmann; George S Baillie
Journal:  FEBS Lett       Date:  2015-02-11       Impact factor: 4.124

Review 9.  The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review).

Authors:  Kuo Yan; Li-Na Gao; Yuan-Lu Cui; Yi Zhang; Xin Zhou
Journal:  Mol Med Rep       Date:  2016-03-18       Impact factor: 2.952

10.  Evaluation of bronchodialatory and antimicrobial activities of Otostegia fruticosa: A multi-mechanistic approach.

Authors:  Mohd Nazam Ansari; Najeeb Ur Rehman; Aman Karim; Tiegsti Bahta; Khalil Y Abujheisha; Syed Rizwan Ahamad; Faisal Imam
Journal:  Saudi Pharm J       Date:  2020-01-31       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.